Pfizer's Diverse Portfolio Supports a Narrow Moat, Despite Patent Loss Headwinds

Pfizer's foundation remains solid, based on steady cash flows generated from a basket of diverse drugs. The company's large size confers significant competitive advantages in developing new drugs. This heft, combined with a broad portfolio of patent-protected drugs, has helped Pfizer build an economic moat around its business.